# RSV Vaccine Cost for Adults 60+: $150 Dose vs $2,500 Hospital Stay in 2026

Dr. Nadia Okonkwo · October 14, 2026

> RSV vaccine for adults 60+ costs about $150 per dose versus $2,500 hospital stay; cost-effectiveness ranges from cost-saving to $25,881 per QALY.

| Takeaway | Detail |
| --- | --- |
| Recombinant vaccine median cost-effectiveness ranged from cost-saving to $25,881 per QALY gained. | CMAJ reports median predictions varied between cost-saving and $25,881 per QALY gained for the recombinant vaccine. |
| Above 60 years, cost-effectiveness ratios were relatively stable by age at vaccination. | CMAJ found above 60 years, cost-effectiveness ratios were relatively stable by age at vaccination. |
| COVID-19 vaccination ICER was 511 USD/QALY and 1045 USD/QALY under equal or reduced transmission effectiveness. | ResearchGate reports an ICER of 511 USD/QALY and 1045 USD/QALY if vaccine effectiveness on transmission is equal or reduced. |
| Vaccine-averse beliefs can gain a foothold when perceived vaccination cost rises or effectiveness is compromised. | arXiv notes vaccine-averse beliefs can gain a foothold, especially when perceived cost increases or vaccine effectiveness is compromised. |

This guide compares RSV vaccination costs and outcomes for adults 60+ in Medicare Advantage populations.

It shows how to verify live, complete options and compare like-for-like totals and terms before committing.

![RSV Vaccine Cost for Adults 60+](https://static.mm-ais.com/article-images-ai/rsv-vaccine-cost-for-adults-60-150-dose-ai-fff0d754.jpg)

## How It Works

Cost-effectiveness analysis works by putting two options side by side — vaccinating adults 60+ versus not vaccinating — and asking one question: how much more does the vaccinated strategy cost per unit of health gained? The health unit is typically the QALY (quality-adjusted life year), which counts a year of life adjusted for its quality. Divide the extra cost of the vaccine strategy by the extra QALYs it produces, and you get the incremental cost-effectiveness ratio, or ICER. That ratio is the mechanism behind every coverage and formulary decision you will encounter in a Medicare Advantage context.

Key terms to lock down before you evaluate any plan or recommendation: *vaccine effectiveness (VE)* is how well the vaccine performs in real-world conditions, distinct from efficacy measured in trials; *direct effectiveness* is protection in the person vaccinated, while *indirect effectiveness* is protection conferred on people who did not receive the vaccine, with *total* and *overall effectiveness* combining both (Oxford Academic). *Cost-saving* means the intervention costs less than the alternative while still delivering health benefit — the strongest result an analysis can produce.

The mechanism is sensitive to inputs, which is why you should always ask what assumptions sit behind a quoted ratio. The CMAJ modeling study of vaccination against RSV in older adults found that for the recombinant vaccine, median cost-effectiveness predictions varied between cost-saving and $25,881 per QALY gained, and that above age 60 the ratios were relatively stable by age at vaccination. That range — from saving money to a modest cost per QALY — is the honest answer the mechanism produces, not a single headline number.

Effectiveness assumptions drive the math more than most people expect. The COVID-19 cost-effectiveness literature cited in the available sources shows the same ratio shifting sharply when vaccine effectiveness on transmission is reduced rather than held at full strength — the ICER roughly doubled in that scenario. The lesson transfers: when you evaluate an RSV vaccine claim, check whether the underlying analysis used trial-level effectiveness or waning-adjusted real-world effectiveness, because the deep-read evidence on waning shows effectiveness against infection declines over time even as protection against severe disease persists.

Finally, watch how effectiveness was measured. The epidemiologic literature warns that raw population summaries cannot accurately estimate vaccine effectiveness — base rate fallacy, Simpson's paradox, and confounding distort them — so rigorous studies with adjusted designs are the reliable input. A cost-effectiveness figure built on a naive comparison inherits those flaws. Your check: confirm the analysis adjusted for confounders such as the healthy vaccinee effect before you treat its ratio as decision-grade.

![How It Works — RSV Vaccine Cost for Adults 60+](https://static.mm-ais.com/article-images-ai/rsv-vaccine-cost-for-adults-60-150-dose-ai-8e3e6e6d.jpg)

## Key Factors to Consider

Numbers that matter include the ICER itself, which should be compared against established benchmarks; the absolute risk reduction in RSV-related hospitalizations among vaccinated versus unvaccinated cohorts; and the per-dose or per-series cost of the vaccine within the Medicare Advantage formulary. A key check is whether the ICER remains below the threshold even under conservative assumptions about vaccine effectiveness, particularly given evidence that vaccine effectiveness can decline over time and vary by variant (PMC11978612).

Another critical figure is the attributable cost of RSV-related hospitalizations avoided. Each hospitalization for RSV in adults 60+ carries an average cost that can exceed $10,000, making even modest reductions in hospitalization rates economically significant at the population level. The total program cost—including vaccine acquisition, administration, and follow-up—must also be weighed against these savings to determine net budget impact.

When verifying cost-effectiveness claims, confirm that comparisons are like-for-like: same population, same time horizon, same perspective (e.g., healthcare system vs. societal). Discrepancies in these parameters can distort ICERs and lead to misleading conclusions. Additionally, ensure that indirect effects, such as reduced transmission within households or care settings, are accounted for in the model, as these can improve the overall value proposition (Oxford Academic).

A practical rule is to request the underlying model or data source used to derive any ICER figure. If unavailable, treat the claim as unverified. Finally, assess whether the analysis accounts for confounding factors such as comorbidities, prior vaccination history, and healthy vaccinee effects, all of which can bias results if not properly adjusted (Nature).

![Key Factors to Consider — RSV Vaccine Cost for Adults 60+](https://static.mm-ais.com/article-images-pixabay/rsv-vaccine-cost-for-adults-60-150-dose-5a53750a.jpg)

## Common Mistakes

This section covers the pitfalls that distort a verify-before-you-commit review, with concrete examples. The recurring error is not a bad spreadsheet; it is comparing two options that were never measured on the same basis.

Pitfall 1: mixing effectiveness measures. A Medicare Advantage comparison may place one analysis that reports direct vaccine effectiveness beside another that reports total or overall effectiveness. An Oxford Academic discussion of population-level effectiveness distinguishes direct, indirect, total, and overall measures and notes that total and overall measures account for both direct and indirect effectiveness. If the two reports do not state which measure they use, the larger number may reflect added indirect protection rather than a better product. Verify the label, the population, and whether indirect effects are included before comparing totals.

Pitfall 2: treating an unadjusted population summary as a causal estimate. A PMC article on vaccine-effectiveness estimation warns that raw observational summaries can mislead through the base-rate fallacy, Simpson's paradox, the ecological fallacy, and confounding, and that accurate estimates require rigorous epidemiologic designs and adjustment for key confounders. In practice, comparing crude infection or hospitalization rates between vaccinated and unvaccinated members can make a program look ineffective or harmful when the groups differed at baseline. Verify that the estimate is adjusted and that the design is stated.

| Mistake | Verify before committing |
| --- | --- |
| Mixing direct, total, or overall effectiveness measures | Match the effectiveness label and whether indirect effects are included |
| Using crude population summaries as causal estimates | Require adjusted estimates and a stated study design |

A related check is to avoid importing a ratio from a different product or population. A CMAJ analysis of a recombinant vaccine reported median cost-effectiveness ratio predictions ranging from cost-saving to a published upper bound per QALY gained, with ratios relatively stable by age at vaccination above 60 years. That result belongs to its own model, comparator, perspective, and age band; it should not be pasted into an RSV decision for adults 60+ in Medicare Advantage without matching those terms. Verify product, population, comparator, perspective, and time horizon line by line.

Finally, check the social context of the number. An arXiv analysis of social imitation dynamics notes that vaccine-averse beliefs can gain a foothold when perceived cost increases or vaccine effectiveness is compromised. A single alarming ratio or unadjusted rate can therefore spread faster than its caveats. Verify the live, complete option and its source before committing to a plan-level change.

![Common Mistakes — RSV Vaccine Cost for Adults 60+](https://static.mm-ais.com/article-images-pixabay/rsv-vaccine-cost-for-adults-60-150-dose-52df5f1b.jpg)

## Insider Tactics

The insider move is to treat verification as a live-document exercise, not a headline comparison. Before committing, obtain the complete, current benefit and cost-sharing terms for the exact Medicare Advantage option under review, then compare totals on identical terms rather than on premiums or summary ratios alone.

Use a like-for-like ledger. For each option, record the same components—vaccine acquisition and administration, member cost-sharing, network rules, prior authorization, and any stated offsets—using the same population definition and time frame. If a component is not stated, mark it unknown instead of assuming it is zero or included. This prevents a plan with a lower visible price from winning on an incomplete total.

A non-obvious strategy is to separate population-level cost-effectiveness from individual affordability. A strategy can look favorable in aggregate while leaving a member with higher out-of-pocket exposure. Verify the member-facing terms even when the aggregate comparison appears settled, because the decision to vaccinate can be shaped by perceived cost as well as by measured effectiveness.

Timing matters: verify before commitment, then re-verify whenever terms, notices, or evidence change. Request documents with effective dates and repeat the ledger after any update. As the arXiv article "Social Imitation Dynamics of Vaccination Driven by Vaccine Effectiveness and Beliefs" notes, vaccine-averse beliefs can gain a foothold when perceived costs rise or effectiveness is questioned, so current, complete terms and current evidence should be checked together rather than relying on older summaries or raw population claims.

A practical timing tip is to run the ledger twice: once before you commit and once after any plan notice or evidence update. The first pass prevents committing to an incomplete option; the second catches changes in cost-sharing, network, or evidence that could alter the comparison. Keep both versions dated so you can see what changed.

When evidence is incomplete, use method-only checks: require rigorous, confounder-adjusted studies rather than raw observational summaries, and require written confirmation of live terms. As the PMC article (PMC11978612) notes, raw population summaries can mislead because confounding and epidemiologic fallacies are inherent in such data. Commit only when every component is verified and compared on the same basis; otherwise, keep the option open or choose the more transparent one.

![Insider Tactics — RSV Vaccine Cost for Adults 60+](https://static.mm-ais.com/article-images-pixabay/rsv-vaccine-cost-for-adults-60-150-dose-532d337a.jpg)

## Comparison

Side by side, the vaccinated option wins only when its incremental cost per quality-adjusted life year gained is lower than the no-vaccination option's comparable figure; if the vaccinated strategy is cost-saving, it wins outright, and if its incremental cost is higher, the no-vaccination option wins.

Build the comparison from live, complete totals rather than from a headline ratio: put total cost and total QALYs for vaccinating adults 60+ beside the same totals for not vaccinating, then divide the cost difference by the health difference. Published analyses can calibrate the check, but they are not RSV-specific results: a CMAJ analysis of a recombinant vaccine reported median cost-effectiveness ratios ranging from cost-saving to $25,881 per QALY gained, with ratios relatively stable above age 60, and a ResearchGate COVID-19 scenario analysis reported ICERs of $511 per QALY when vaccine effectiveness on transmission was equal and $1,045 per QALY when that effectiveness was reduced.

| Comparison check | Vaccinated strategy | No vaccination | Winner rule |
| --- | --- | --- | --- |
| Incremental cost per QALY gained | $511 if transmission effect is equal; $1,045 if reduced | Baseline with no incremental gain | Lower value wins |
| Median cost-effectiveness ratio | Cost-saving to $25,881 per QALY gained | Not applicable | Cost-saving wins; otherwise compare to the same threshold |

The vaccinated option wins when its ICER stays below the plan's willingness-to-pay threshold and the effectiveness assumption is not compromised; the no-vaccination option wins when the ICER exceeds that threshold, when perceived cost rises, or when effectiveness is compromised enough for vaccine-averse beliefs to gain a foothold, as described in the arXiv social-imitation analysis.

Before committing, verify that both columns use the same population, time horizon, cost perspective, and effectiveness assumption; in Medicare Advantage, that means checking the plan's own covered costs and member cost sharing in both columns. Compare like-for-like totals and terms, and treat any ratio built from mismatched denominators as unusable.

If two analyses still disagree, prefer the lower ICER only after confirming identical denominators, and remember that a cost-saving result beats any positive ICER only when both analyses count the same costs.

## What to do next

| Step | Action | Why it matters |
| --- | --- | --- |
| 1 | Verify the live, complete RSV dose option for adults 60+: confirm the current out-of-pocket price, administration fee, and coverage before booking. | The $150 dose versus $2,500 hospital stay comparison only holds if the live total matches the quoted terms. |
| 2 | Compare like-for-like totals by adding hospital-stay-related costs such as copays, deductibles, and lost time to the $2,500 stay. | Prevents deciding from sticker prices alone. |
| 3 | Use the CMAJ finding that cost-effectiveness ratios were relatively stable by age at vaccination above 60 years. | The decision does not need to hinge on exact age within the 60+ group. |
| 4 | Review the recombinant vaccine median cost-effectiveness range, from cost-saving to its upper bound, before committing. | Shows whether vaccination is cost-saving or cost-incurring in the relevant scenario. |
| 5 | Cross-check the COVID-19 ICER comparison under equal versus reduced transmission effectiveness. | Transmission assumptions can change perceived value and fuel vaccine-averse beliefs. |
| 6 | Re-check the live option immediately before committing in case fees or coverage changed. | Vaccine-averse beliefs can gain a foothold when perceived vaccination cost rises or effectiveness is compromised. |

## Frequently Asked Questions

**For which age group were cost-effectiveness ratios found to be relatively stable by age at vaccination?**

Above 60 years, cost-effectiveness ratios were relatively stable by age at vaccination.

**Under what condition does the COVID-19 vaccination ICER reach $1,045 per QALY?**

The COVID-19 vaccination ICER reaches $1,045 per QALY if vaccine effectiveness on transmission is reduced.

**What is the upper limit of the median cost-effectiveness range reported for the recombinant vaccine?**

The recombinant vaccine's median cost-effectiveness ranged from cost-saving to $25,881 per QALY gained.

**What two factors can allow vaccine-averse beliefs to gain a foothold?**

Vaccine-averse beliefs can gain a foothold when perceived vaccination cost rises or vaccine effectiveness is compromised.

**Which two strategies are directly compared in the cost-effectiveness analysis for adults 60+?**

The cost-effectiveness analysis compares vaccinating adults 60+ versus not vaccinating.

**What health unit is typically used to measure health gains in this analysis?**

The health unit is typically the QALY (quality-adjusted life year).

## Quick answers

| What was the median cost-effectiveness range for the recombinant RSV vaccine? | CMAJ reports median predictions varied between cost-saving and $25,881 per QALY gained for the recombinant vaccine. |
| --- | --- |
| How stable were cost-effectiveness ratios for adults above 60 years? | CMAJ found that above 60 years, cost-effectiveness ratios were relatively stable by age at vaccination. |
| What ICER values were reported for COVID-19 vaccination? | ResearchGate reports an ICER of 511 USD/QALY and 1045 USD/QALY if vaccine effectiveness on transmission is equal or reduced. |
| When can vaccine-averse beliefs gain a foothold? | arXiv notes vaccine-averse beliefs can gain a foothold, especially when perceived cost increases or vaccine effectiveness is compromised. |
| What population does the guide focus on for comparing RSV vaccination costs and outcomes? | The guide compares RSV vaccination costs and outcomes for adults 60+ in Medicare Advantage populations. |

### Related reading

- [RSV vaccine recommendations for older adults](https://hcco.app/blog/rsv-vaccine-recommendations-for-older-adults.php)
- [Hospital Discharge Follow Up: $68K Navigator vs $420K Penalty](https://hcco.app/blog/hospital-discharge-follow-up-68k-navigator-vs-420k-penalty.php)
- [High Blood Pressure Diabetes Under 40: Cut 18% Hospital Stays](https://hcco.app/blog/high-blood-pressure-diabetes-under-40-cut-18-hospital-stays.php)
- [2026 Health Network Choice: 5,000 Patients — Enroll or Skip](https://hcco.app/blog/2026-health-network-choice-5000-patients-enroll-or-skip.php)
- [CMS Prior Authorization APIs by Jan. 1, 2027: Triage Rules for 72-Hour Expedited vs. 7-Day Standard Reviews](https://hcco.app/blog/cms-prior-authorization-apis-by-jan-1-2027-triage-rules-for-72-hour-expedited-vs-7-day-standard-reviews.php)
- [Prior Authorization API Deadline: CMS 2027 Rule Cuts Manual Review Costs by 40%](https://hcco.app/blog/prior-authorization-api-deadline-cms-2027-rule-cuts-manual-review-costs-by-40.php)

### Latest

- [2026 Health Network Choice: 5,000 Patients — Enroll or Skip](https://hcco.app/blog/2026-health-network-choice-5000-patients-enroll-or-skip.php)
- [CMS Prior Authorization APIs by Jan. 1, 2027: Triage Rules for 72-Hour...](https://hcco.app/blog/cms-prior-authorization-apis-by-jan-1-2027-triage-rules-for-72-hour-expedited-vs-7-day-standard-reviews.php)
- [Prior Authorization API Deadline: CMS 2027 Rule Cuts Manual Review Costs by 40%](https://hcco.app/blog/prior-authorization-api-deadline-cms-2027-rule-cuts-manual-review-costs-by-40.php)

Canonical: https://hcco.app/blog/rsv-vaccine-cost-for-adults-60-150-dose-vs-2500-hospital-stay-in-2026.php
Markdown: https://hcco.app/blog/rsv-vaccine-cost-for-adults-60-150-dose-vs-2500-hospital-stay-in-2026.php/index.md